These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. The heterogeneous nature of Cu2+ interactions with Alzheimer's amyloid-β peptide. Drew SC; Barnham KJ Acc Chem Res; 2011 Nov; 44(11):1146-55. PubMed ID: 21714485 [TBL] [Abstract][Full Text] [Related]
6. Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Adlard PA; Cherny RA; Finkelstein DI; Gautier E; Robb E; Cortes M; Volitakis I; Liu X; Smith JP; Perez K; Laughton K; Li QX; Charman SA; Nicolazzo JA; Wilkins S; Deleva K; Lynch T; Kok G; Ritchie CW; Tanzi RE; Cappai R; Masters CL; Barnham KJ; Bush AI Neuron; 2008 Jul; 59(1):43-55. PubMed ID: 18614028 [TBL] [Abstract][Full Text] [Related]
7. Clioquinol reduces zinc accumulation in neuritic plaques and inhibits the amyloidogenic pathway in AβPP/PS1 transgenic mouse brain. Wang T; Wang CY; Shan ZY; Teng WP; Wang ZY J Alzheimers Dis; 2012; 29(3):549-59. PubMed ID: 22269164 [TBL] [Abstract][Full Text] [Related]
8. Copper(I) and copper(II) inhibit Aβ peptides proteolysis by insulin-degrading enzyme differently: implications for metallostasis alteration in Alzheimer's disease. Grasso G; Pietropaolo A; Spoto G; Pappalardo G; Tundo GR; Ciaccio C; Coletta M; Rizzarelli E Chemistry; 2011 Feb; 17(9):2752-62. PubMed ID: 21274957 [TBL] [Abstract][Full Text] [Related]
9. Differential modulation of Alzheimer's disease amyloid beta-peptide accumulation by diverse classes of metal ligands. Caragounis A; Du T; Filiz G; Laughton KM; Volitakis I; Sharples RA; Cherny RA; Masters CL; Drew SC; Hill AF; Li QX; Crouch PJ; Barnham KJ; White AR Biochem J; 2007 Nov; 407(3):435-50. PubMed ID: 17680773 [TBL] [Abstract][Full Text] [Related]
10. Gold nanoparticle-capped mesoporous silica-based H Yang L; Yin T; Liu Y; Sun J; Zhou Y; Liu J Acta Biomater; 2016 Dec; 46():177-190. PubMed ID: 27619837 [TBL] [Abstract][Full Text] [Related]
11. Clioquinol decreases amyloid-beta burden and reduces working memory impairment in a transgenic mouse model of Alzheimer's disease. Grossi C; Francese S; Casini A; Rosi MC; Luccarini I; Fiorentini A; Gabbiani C; Messori L; Moneti G; Casamenti F J Alzheimers Dis; 2009; 17(2):423-40. PubMed ID: 19363260 [TBL] [Abstract][Full Text] [Related]
12. Radioiodinated clioquinol as a biomarker for beta-amyloid: Zn complexes in Alzheimer's disease. Opazo C; Luza S; Villemagne VL; Volitakis I; Rowe C; Barnham KJ; Strozyk D; Masters CL; Cherny RA; Bush AI Aging Cell; 2006 Feb; 5(1):69-79. PubMed ID: 16441845 [TBL] [Abstract][Full Text] [Related]
13. Increasing intracellular bioavailable copper selectively targets prostate cancer cells. Cater MA; Pearson HB; Wolyniec K; Klaver P; Bilandzic M; Paterson BM; Bush AI; Humbert PO; La Fontaine S; Donnelly PS; Haupt Y ACS Chem Biol; 2013 Jul; 8(7):1621-31. PubMed ID: 23656859 [TBL] [Abstract][Full Text] [Related]
14. Design, selection, and characterization of thioflavin-based intercalation compounds with metal chelating properties for application in Alzheimer's disease. Rodríguez-Rodríguez C; Sánchez de Groot N; Rimola A; Alvarez-Larena A; Lloveras V; Vidal-Gancedo J; Ventura S; Vendrell J; Sodupe M; González-Duarte P J Am Chem Soc; 2009 Feb; 131(4):1436-51. PubMed ID: 19133767 [TBL] [Abstract][Full Text] [Related]
15. Disaggregation ability of different chelating molecules on copper ion-triggered amyloid fibers. Zhu L; Han Y; He C; Huang X; Wang Y J Phys Chem B; 2014 Aug; 118(31):9298-305. PubMed ID: 25051063 [TBL] [Abstract][Full Text] [Related]
16. Cell cycle arrest in cultured neuroblastoma cells exposed to a bis(thiosemicarbazonato) metal complex. Bica L; Meyerowitz J; Parker SJ; Caragounis A; Du T; Paterson BM; Barnham KJ; Crouch PJ; White AR; Donnelly PS Biometals; 2011 Feb; 24(1):117-33. PubMed ID: 20931265 [TBL] [Abstract][Full Text] [Related]
17. Regulation of copper and iron homeostasis by metal chelators: a possible chemotherapy for Alzheimer's disease. Robert A; Liu Y; Nguyen M; Meunier B Acc Chem Res; 2015 May; 48(5):1332-9. PubMed ID: 25946460 [TBL] [Abstract][Full Text] [Related]
18. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Ritchie CW; Bush AI; Mackinnon A; Macfarlane S; Mastwyk M; MacGregor L; Kiers L; Cherny R; Li QX; Tammer A; Carrington D; Mavros C; Volitakis I; Xilinas M; Ames D; Davis S; Beyreuther K; Tanzi RE; Masters CL Arch Neurol; 2003 Dec; 60(12):1685-91. PubMed ID: 14676042 [TBL] [Abstract][Full Text] [Related]
19. Soluble amyloid beta1-28-copper(I)/copper(II)/Iron(II) complexes are potent antioxidants in cell-free systems. Baruch-Suchodolsky R; Fischer B Biochemistry; 2008 Jul; 47(30):7796-806. PubMed ID: 18598056 [TBL] [Abstract][Full Text] [Related]
20. NMR reveals anomalous copper(II) binding to the amyloid Abeta peptide of Alzheimer's disease. Hou L; Zagorski MG J Am Chem Soc; 2006 Jul; 128(29):9260-1. PubMed ID: 16848423 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]